These data suggest that metabolically based therapies associated with improvements in adipose tissue insulin sensitivity such as those targeting GLP-1 receptors, PPARs, and FGF-21 may not only reduce steatosis by reducing NEFA flux but may also potentially exert antifibrotic effects by inhibiting endotrophin and BCAAs (Figure 3). This evidence concerns the gene INS and steatosis.